Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 532815 | NSE Symbol : SMSPHARMA | ISIN : INE812G01025 | Industry : Pharmaceuticals - Indian - Bulk Drugs |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
27-Mar-2025	27-Mar-2025	Conversion	Allotment of Equity shares pursuant to conversion of warrants.
05-Feb-2025	12-Feb-2025	Quarterly Results	Quarterly Results SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 ,inter alia, to consider and approve Financial Results for the quarter ended 31st December, 2024 Outcome of the Board Meeting and Financial Results for the quarter ended 31.12.2024 Submission of updated Code for Regulation and Prohibition of Insider Trading. (As Per BSE Announcement Dated on: 12/02/2025)
01-Nov-2024	08-Nov-2024	Quarterly Results	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2024 inter alia to consider and approve financial results for the quarter and half year ended 30th September 2024. Outcome of the Board Meeting and Financial Results (As Per BSE Announcement Dated on: 08/11/2024)
29-Jul-2024	05-Aug-2024	Quarterly Results	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2024 inter alia to consider and approve Intimation of Board Meeting SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2024 ,inter alia, to consider and approve Update on board meeting - Change in venue of Board Meeting Read less.. (As Per BSE Announcement Dated on 02.08.2024) Outcome of Board Meeting Outcome of Board Meeting and Financial Results for the quarter ended 30th June, 2024. (As per BSE Announcement Dated on 05/08/2024)
22-May-2024	29-May-2024	Final Dividend	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve We would like to inform you that a meeting of the Board of Directors of the Company scheduled to be held on Wednesday 29th May 2024 at the Registered Office of the Company Outcome of Board Meeting Intimation under Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015. (As per BSE Announcement Dated on 29/05/2024)
02-Feb-2024	08-Feb-2024	Quarterly Results	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve the Financial Results of the Company for the third quarter ended on 31st December 2023 Outcome of the Board Meeting - Approval of financial results for the quarter ended 31st December, 2023 and approval for issue of share warrants on preferential basis Approval for fund raising by way of issue of warrants on preferential basis (As Per BSE Announcement Dated on: 08/02/2024)
01-Nov-2023	08-Nov-2023	Quarterly Results	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/11/2023 inter alia to consider and approve the financial results for the quarter ended 30th September 2023 Outcome and Financial Results for the quarter ended 30th September, 2023 Outcome of Board Meeting and Financial Results for the second quarter and half year ended 30th September, 2023 (As Per BSE Announcement Dated on 08.11.2023)
01-Aug-2023	08-Aug-2023	Quarterly Results	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2023 inter alia to consider and approve un-audited Financial Results (Standalone & Consolidated) for the First Quarter ended 30th June 2023. Outcome of Board Meeting and Financial Results (As Per BSE Announcement dated on 08.08.2023)
17-May-2023	24-May-2023	Final Dividend	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 inter alia to consider and approve 1. The Audited Financial Statements (Standalone & Consolidated) for the fourth quarter and financial year ended 31st March 2023. 2.To consider recommend dividend if any for the financial year 2022-2023 Recommended the Dividend of Re.0.30 Paise (30%) per equity share of face value of Rs.1/-each for the financial year 2022-23 Outcome of Board Meeting and Financial Results (As Per BSE Announcement Dated on 24.05.2023)
31-Jan-2023	09-Feb-2023	Quarterly Results	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 inter alia to consider and approve Notice of Board Meeting & Intimation Outcome of Board Meeting held on 09th February, 2023 (As Per BSE Announcement Dated on 09/02/2023)
05-Nov-2022	12-Nov-2022	Quarterly Results	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 inter alia to consider and approve un-audited Financial Results for the second quarter and half year ended 30th September 2022. outcome of the Board Meeting held on 12-Nov-2022 to consider financial statements for the period ended September 2022 (As Per BSE Announcement Dated 12.11.2022)
05-Aug-2022	13-Aug-2022	Quarterly Results	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2022 inter alia to consider and approve un audited financial results for the quarter ended 30th June 2022 SMS Pharmaceuticals Limited has informed the Exchange about Board Meeting held on 13-Aug-2022 to consider financial statements for the period ended June 2022 and Other business matters Financial Results for the first quarter ended 30th June, 2022 Fixation of AGM date, Book Closure and Record Date for AGM (As Per BSE Announcement Dated on 13/08/2022)
23-May-2022	30-May-2022	Accounts	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Notice of Board Meeting & Intimation Recommended the Dividend of 30% per equity share of face value of Rs. 1/-each for the financial year 2021-22 Outcome of Board Meeting held on 30th May, 2022 Correction in the Notes to Financial Results submitted for the Quarter and Year ended 31st March, 2022 (As per BSE Announcement Dated on 30/5/2022) Communication to shareholders on Tax Deduction at Source ('TDS') on dividend payout. (As Per BSE Announcement Dated on 25.08.2022)
03-Feb-2022	09-Feb-2022	Quarterly Results	SMS PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2022 inter alia to consider and approve NOTICE is hereby given pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 and Sec. 173 of the Companies Act 2013 that a meeting of the Board of Directors of the Company will be held on the Wednesday 9th day of February 2022 at the Registered Office of the Company inter alia for the following items: To consider and approve the Un-audited Standalone and Consolidated Financial results of the Company for the Quarter and nine months ended as on 31st December 2021. Please be informed that Insider Trading window of SMS Pharmaceuticals Limited shall remain closed till 11th February 2022 in view of the above mentioned Board Meeting. With reference to the above subject, we would like to inform you that Board of Directors of the Company at their meeting held today, inter-alia considered and approved the following: 1. The Standalone and Consolidated Un-audited Financial Results for the third Quarter and Nine months ended 31st December, 2021 along with the Limited Review Report. (As per BSE Announcement Dated on 09/02/2022)
08-Nov-2021	12-Nov-2021	Quarterly Results	Quarterly Results With reference to the above subject, we would like to inform you that Board of Directors of the Company at their meeting held today, inter-alia considered and approved the following: 1. The Standalone and Consolidated Un-audited Financial Results for the Quarter and half year ended 30th September, 2021 along with the Limited Review Report. 2. Approved the resignation of Mr. V S Venkatish, Company Secretary and Compliance Officer, and he will be relieved on or before 31st January, 2022. (As per BSE Announcement Dated on 12/11/2021)

1 2

LOGIN HERE

SMS Pharmaceuticals Ltd

Board Meeting